EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing

Asma Naseem, Winston Vetharoy, Thomas E Whittaker, Federica Zinghirino, Antonio Carusillo, Roopkatha Ghosh, Eduardo Gomez-Castaneda, Hashim Ali, Carlo Cipriani, Eugenio Montini, Adrian J Thrasher, Giorgia Santilli und 3 weitere

Molecular Therapy Advances · 2026-09 · 34 (3) · 201816

DOI: 10.1016/j.omta.2026.201816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-09. Verfasst von Asma Naseem und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity & Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, 20…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI Medical Research Council, Ministero dell'Istruzione dell'Università e della Ricerca, Great Ormond Street Hospital Children's Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Translating CRISPR-Cas9-based homology-directed repair (HDR) strategies into clinical application remains a major challenge due to limited standardization, concerns over safety, and efficacy issues. Here, we present a comprehensive and clinically compliant preclinical framework for the ex vivo correction of Wiskott-Aldrich syndrome (WAS) using a CRISPR-Cas9-AAV6 platform targeting hematopoietic stem and progenitor cells (HSPCs). In this study, we established a clinical-compatible platform enabling large-scale manufacturing while preserving HSPC viability, stemness, and multilineage functionality. To overcome low HSPC long-term engraftment, we fine-tuned AAV dosing and transiently modulated p53BP-dependent DNA damage response pathway, achieving significantly improved in vivo correction and repopulation. Importantly, we implemented a multi-tiered genotoxicity assessment strategy, integrating in silico, genome-wide, and orthogonal assays, revealing a largely favorable safety profile with minimal off-target risks and no evidence of clonal dominance or transformation during the study period. Longitudinal in vivo safety monitoring revealed donor-specific rare off-target events and structural variants. This highlights the crucial importance of patient monitoring after transplantation, further emphasized by the identification of a de novo chromosomal rearrangement that could be detected exclusively following cell engraftment in mice. This work offers a robust and adaptable roadmap for future HDR-based gene editing platforms, establishing critical benchmarks for efficacy, safety, and regulatory readiness in the development of advanced therapeutic medicinal products.

Schlagwörter

Stichwörter der Autor:innen

gene editinghematopoietic stem and progenitor cellshomology-directed repairpreclinical

Autor:innen und Institutionen

  • Infection, Immunity & Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, 20 Guilford Street, London WC1N 1DZ, UK.
  • Center for Genomic Medicine and Rare Diseases, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
  • Division of Infection and Immunity, University College London, London, UK.
  • San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Hospital, Milan, Italy.
  • Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
  • NIHR Great Ormond Street Hospital Biomedical Research Centre, 30 Guilford Street, London WC1N 1EH, UK.

Förderung

  • UKRI Medical Research Council
  • Ministero dell'Istruzione dell'Università e della Ricerca
  • Great Ormond Street Hospital Children's Charity
  • Great Ormond Street Hospital for Children
  • Wellcome Trust
  • Jeffrey Modell Foundation

Zitieren

APA

Naseem, A., Vetharoy, W., Whittaker, T. E., Zinghirino, F., Carusillo, A., Ghosh, R., Gomez-Castaneda, E., Ali, H., Cipriani, C., Montini, E., Thrasher, A. J., Santilli, G., Cesana, D., Turchiano, G., & Cavazza, A. (2026). In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing. Molecular Therapy Advances, 34(3), 201816. https://doi.org/10.1016/j.omta.2026.201816

Vancouver

Naseem A, Vetharoy W, Whittaker TE, Zinghirino F, Carusillo A, Ghosh R, et al. In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing. Molecular Therapy Advances. 2026;34(3):201816. doi:10.1016/j.omta.2026.201816

BibTeX
@article{Naseem2026,
  author = {Naseem, Asma and Vetharoy, Winston and Whittaker, Thomas E and Zinghirino, Federica and Carusillo, Antonio and Ghosh, Roopkatha and Gomez-Castaneda, Eduardo and Ali, Hashim and Cipriani, Carlo and Montini, Eugenio and Thrasher, Adrian J and Santilli, Giorgia and Cesana, Daniela and Turchiano, Giandomenico and Cavazza, Alessia},
  title = {In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing},
  journal = {Molecular Therapy Advances},
  year = {2026},
  volume = {34},
  number = {3},
  pages = {201816},
  doi = {10.1016/j.omta.2026.201816}
}
Kostenlos starten →